LENZ Therapeutics Inc (LENZ)vsRoyalty Pharma Plc (RPRX)
LENZ
LENZ Therapeutics Inc
$5.90
-2.64%
HEALTHCARE · Cap: $181.54M
RPRX
Royalty Pharma Plc
$57.80
+1.55%
HEALTHCARE · Cap: $32.78B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 11528% more annual revenue ($2.44B vs $20.99M). RPRX leads profitability with a 33.9% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
LENZ
Avoid31
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LENZ.
Margin of Safety
-64.1%
Fair Value
$34.68
Current Price
$57.80
$23.12 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LENZ
The strongest argument for LENZ centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : LENZ
The primary concerns for LENZ are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
LENZ profiles as a value stock while RPRX is a mature play — different risk/reward profiles.
LENZ carries more volatility with a beta of 1.47 — expect wider price swings.
RPRX is growing revenue faster at 11.0% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 31/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
LENZ Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
LENZ Therapeutics Inc is a pioneering biopharmaceutical company focused on developing innovative therapies for neurological disorders, with an emphasis on addressing significant unmet needs in the central nervous system (CNS). Leveraging advanced drug formulation and delivery technologies, the company boasts a robust pipeline of proprietary assets designed to improve patient outcomes. With strategic partnerships and a strong commitment to rigorous clinical research, LENZ is well-positioned for substantial growth and aims to establish itself as a key player in the biopharmaceutical sector, capitalizing on emerging opportunities within the evolving healthcare market.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?